search

Kiniksa Pharmaceuticals Ltd (KNSA)

OverviewChartFinancialsStatisticsEarningsInsider transactionsETFsNews

News

Real-time news feed aggregating press releases, regulatory filings, and global media coverage for a single company, filterable by date range, relevance score, and sentiment classification. Each article is tagged with company-specific and overall market sentiment — allowing investors to separate fundamental catalysts from broader market noise and monitor how the narrative around a stock is evolving over time.

Relevance *
40
Kiniksa Pharmaceuticals International, plc (KNSA) Q3 Earnings and Revenues Surpass Estimates
Oct 27, 2026

Kiniksa Pharmaceuticals International, plc (KNSA) Q3 Earnings and Revenues Surpass Estimates

Kiniksa Pharmaceuticals International, plc (KNSA) reported strong Q3 2026 results, with earnings of $0.56 per share significantly beating the Zacks Consensus Estimate of $0.32, and revenues of $285.97 million also surpassing estimates. The company has a Zacks Rank #3 (Hold), indicating it is expected to perform in line with the market. KNSA shares have seen a substantial increase of 76.9% year-to-date, outperforming the S&P 500.
Company relevance
100.00%
Company sentiment
Bullish
Overall sentiment
Bullish